Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Histologically proven mRCC.~* Administration of one of the systemic agents in use for the treatment of mRCC (no more than three prior systemic therapy regimens). Patients with at least 6 months of 1st line treatment and a bone event may be included.~* More than 1 bone metastasis.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.~* Adequate renal function (serum creatinine ≤ 200 mmol/L or creatinine clearance ≥ 30 mL/min according to Cockroft formula or MDRD formula for patients older than 65 years).~* Covered by a medical insurance.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.~* Signed informed consent.~* Accepting to use effective contraception during study treatment and within 5 months after final dose of study therapy.~Exclusion Criteria:~* Prior bisphosphonate or denosumab treatment in the year before inclusion.~* Imminent or ongoing nerve or spinal compression as per the investigator's judgement.~* Ongoing first-line therapy, started for less than 6 months (patients with BM at time of metastases diagnosis will initially benefit from the angiogenesis targeted agents used and are not at higher risk).~* Anticancer treatment under investigation.~* Paraneoplastic hypercalcemia (corrected total calcium \> 2.7 mmol/L).~* Grade 4 toxicity under previous targeted agents.~* Liver failure (AST and/or ALT ≥ 5.0 x upper limit of normal (ULN) or total bilirubin beyond normal limits).~* Severe hypocalcaemia \> 2.8 mmol/l.~* Fructose intolerance.~* Invasive dental procedure (i.e. tooth extraction, dental implants, oral surgery) within the 10 days prior to randomization or required dental procedures at the pre-inclusion dental examination.~* Psychological, familial, sociological, geographical conditions that would limit compliance with study protocol requirements.~* Pregnant or breastfeeding woman. Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior inclusion.~* Life expectancy ≤ 3 months.~* Participation to another clinical trial that might interfere with the evaluation of the main criterion.~* Known hypersensitivity to the active substance or to any of the excipients of bisphosphonate or denosumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): bone targeted treatment (denosumab or zoledronic acid)
- Arm B (Type: NO_INTERVENTION): no specific treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).